Skip to main content
Erschienen in: Clinical Rheumatology 7/2016

26.02.2016 | Original Article

Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis

verfasst von: Ivone Silva, Cristiana Almeida, Andreia Teixeira, José Oliveira, Carlos Vasconcelos

Erschienen in: Clinical Rheumatology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Impaired angiogenesis in systemic sclerosis has a major role in tissue injury pathogenesis. Our objective was to determine whether angiogenic biomarkers (vascular endothelial growth factor (VEGF), endoglin, and endostatin) are related to microvascular damage and to determine their predictive value for new digital ulcers (DU). The main outcome of the study was the occurrence of a new digital ulcer during 3-year follow-up. This prospective longitudinal study was performed between October 2011 and December 2014. Seventy-seven patients definitely diagnosed with systemic sclerosis where divided into two groups: those with active DU at baseline and those with no DU until enrollment. Patients were matched by sex and age with healthy controls. Serum levels of VEGF, endoglin, and endostatin were measured at enrollment, and several nailfold videocapillaroscopies were performed during the 3-year follow-up. Serum levels of VEGF were lower (245.06, 158.68–347.33; p < 0.001) and those of endoglin were higher (3.013, 1.463–7.023; p < 0.001) in patients with active DU than those with no DU history (339.49, 202.00–730.93/1.879, 0.840–3.280), and they were higher than those found in controls (178.030, 101.267–222.102)/0.277, 0.154–0.713), respectively. No differences in endostatin levels were found between groups (p = 0.450). Endoglin was the only biomarker significantly different (p = 0.031) between patients with diffuse versus limited systemic sclerosis and between early, active, and late patterns (p = 0.020). VEGF was identified as an independent predictor for the development of new DU. Our study confirmed the relationship between angiogenic vascular biomarkers and the occurrence of DU. Endoglin and VEGF serum levels are potential risk factors, and VEGF has a predictive value for the occurrence of new DU.
Literatur
1.
Zurück zum Zitat Avouac J, Vallucci M, Smith V, Senet P, Ruiz B, Sulli A et al (2013) Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. Arthritis Res Ther 15(2):R55CrossRefPubMedPubMedCentral Avouac J, Vallucci M, Smith V, Senet P, Ruiz B, Sulli A et al (2013) Correlations between angiogenic factors and capillaroscopic patterns in systemic sclerosis. Arthritis Res Ther 15(2):R55CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Silva I, Almeida J, Vasconcelos C (2015) A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients. Autoimmun Rev 14(2):140–52CrossRefPubMed Silva I, Almeida J, Vasconcelos C (2015) A PRISMA-driven systematic review for predictive risk factors of digital ulcers in systemic sclerosis patients. Autoimmun Rev 14(2):140–52CrossRefPubMed
3.
Zurück zum Zitat Herrick AL (2013) Management of Raynaud’s phenomenon and digital ischemia. Curr Rheumatol Rep 15(1):303CrossRefPubMed Herrick AL (2013) Management of Raynaud’s phenomenon and digital ischemia. Curr Rheumatol Rep 15(1):303CrossRefPubMed
4.
Zurück zum Zitat Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 81(2):139–53CrossRefPubMed Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G et al (2002) Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 81(2):139–53CrossRefPubMed
5.
Zurück zum Zitat Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Guiducci S et al (2010) Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatol (Oxford, England) 49(7):1374–82CrossRef Amanzi L, Braschi F, Fiori G, Galluccio F, Miniati I, Guiducci S et al (2010) Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatol (Oxford, England) 49(7):1374–82CrossRef
6.
Zurück zum Zitat Rabquer BJ, Koch AE (2012) Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 14(1):56–63CrossRefPubMed Rabquer BJ, Koch AE (2012) Angiogenesis and vasculopathy in systemic sclerosis: evolving concepts. Curr Rheumatol Rep 14(1):56–63CrossRefPubMed
7.
Zurück zum Zitat Lambova SN, Muller-Ladner U (2010) Capillaroscopic pattern in systemic sclerosis—an association with dynamics of processes of angio- and vasculogenesis. Microvasc Res 80(3):534–9CrossRefPubMed Lambova SN, Muller-Ladner U (2010) Capillaroscopic pattern in systemic sclerosis—an association with dynamics of processes of angio- and vasculogenesis. Microvasc Res 80(3):534–9CrossRefPubMed
8.
Zurück zum Zitat Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4(6):R11CrossRefPubMedPubMedCentral Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti ML, Guiducci S et al (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4(6):R11CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Guiducci S, Distler O, Distler JH, Matucci-Cerinic M (2008) Mechanisms of vascular damage in SSc—implications for vascular treatment strategies. Rheumatol (Oxford, England) 47(Suppl 5):v18–20CrossRef Guiducci S, Distler O, Distler JH, Matucci-Cerinic M (2008) Mechanisms of vascular damage in SSc—implications for vascular treatment strategies. Rheumatol (Oxford, England) 47(Suppl 5):v18–20CrossRef
10.
Zurück zum Zitat Serrati S, Chilla A, Laurenzana A, Margheri F, Giannoni E, Magnelli L et al (2013) Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor beta-dependent mesenchymal-to-mesenchymal transition. Arthritis Rheum 65(1):258–69CrossRefPubMed Serrati S, Chilla A, Laurenzana A, Margheri F, Giannoni E, Magnelli L et al (2013) Systemic sclerosis endothelial cells recruit and activate dermal fibroblasts by induction of a connective tissue growth factor (CCN2)/transforming growth factor beta-dependent mesenchymal-to-mesenchymal transition. Arthritis Rheum 65(1):258–69CrossRefPubMed
11.
Zurück zum Zitat Distler JH, Strapatsas T, Huscher D, Dees C, Akhmetshina A, Kiener HP et al (2011) Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Ann Rheum Dis 70(7):1197–202CrossRefPubMed Distler JH, Strapatsas T, Huscher D, Dees C, Akhmetshina A, Kiener HP et al (2011) Dysbalance of angiogenic and angiostatic mediators in patients with mixed connective tissue disease. Ann Rheum Dis 70(7):1197–202CrossRefPubMed
12.
Zurück zum Zitat Farouk HM, Hamza SH, El Bakry SA, Youssef SS, Aly IM, Moustafa AA et al (2013) Dysregulation of angiogenic homeostasis in systemic sclerosis. Int J Rheum Dis 16(4):448–54CrossRefPubMed Farouk HM, Hamza SH, El Bakry SA, Youssef SS, Aly IM, Moustafa AA et al (2013) Dysregulation of angiogenic homeostasis in systemic sclerosis. Int J Rheum Dis 16(4):448–54CrossRefPubMed
13.
Zurück zum Zitat Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A et al (2008) Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatol (Oxford, England) 47(7):972–5CrossRef Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A et al (2008) Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatol (Oxford, England) 47(7):972–5CrossRef
14.
Zurück zum Zitat O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277–85CrossRefPubMed O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS et al (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277–85CrossRefPubMed
15.
Zurück zum Zitat Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43(4):889–93CrossRefPubMed Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, Devulder B (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43(4):889–93CrossRefPubMed
16.
Zurück zum Zitat Committee SfSCotARADaTC. Preliminary criteria for the classification of systemic sclerosis (scleroderma). 1980;23:581–90. Committee SfSCotARADaTC. Preliminary criteria for the classification of systemic sclerosis (scleroderma). 1980;23:581–90.
17.
Zurück zum Zitat LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. The Journal of rheumatology 15(2):202–5PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. The Journal of rheumatology 15(2):202–5PubMed
18.
Zurück zum Zitat Cutolo M, Pizzorni C, Secchi ME, Sulli A (2008) Capillaroscopy. Best Prac Res Clin Rheumatol 22(6):1093–108CrossRef Cutolo M, Pizzorni C, Secchi ME, Sulli A (2008) Capillaroscopy. Best Prac Res Clin Rheumatol 22(6):1093–108CrossRef
19.
Zurück zum Zitat Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26(10):2159–67PubMed Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA et al (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26(10):2159–67PubMed
20.
Zurück zum Zitat Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J et al (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95(1):109–16CrossRefPubMed Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J et al (2004) Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 95(1):109–16CrossRefPubMed
21.
Zurück zum Zitat Coral-Alvarado PX, Garces MF, Caminos JE, Iglesias-Gamarra A, Restrepo JF, Quintana G (2010) Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol 2010 Coral-Alvarado PX, Garces MF, Caminos JE, Iglesias-Gamarra A, Restrepo JF, Quintana G (2010) Serum endoglin levels in patients suffering from systemic sclerosis and elevated systolic pulmonary arterial pressure. Int J Rheumatol 2010
22.
Zurück zum Zitat Morris E, Chrobak I, Bujor A, Hant F, Mummery C, Ten Dijke P et al (2011) Endoglin promotes TGF-beta/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 226(12):3340–8CrossRefPubMedPubMedCentral Morris E, Chrobak I, Bujor A, Hant F, Mummery C, Ten Dijke P et al (2011) Endoglin promotes TGF-beta/Smad1 signaling in scleroderma fibroblasts. J Cell Physiol 226(12):3340–8CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Michalska-Jakubus M, Kowal-Bielecka O, Chodorowska G, Bielecki M, Krasowska D (2011) Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatol (Oxford, England) 50(4):746–55CrossRef Michalska-Jakubus M, Kowal-Bielecka O, Chodorowska G, Bielecki M, Krasowska D (2011) Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatol (Oxford, England) 50(4):746–55CrossRef
24.
Zurück zum Zitat Ichimura Y, Asano Y, Akamata K, Aozasa N, Noda S, Taniguchi T et al (2013) Serum angiopoietin-like protein 3 levels: possible correlation with progressive skin sclerosis, digital ulcers and pulmonary vascular involvement in patients with systemic sclerosis. Acta Derm Venereol Ichimura Y, Asano Y, Akamata K, Aozasa N, Noda S, Taniguchi T et al (2013) Serum angiopoietin-like protein 3 levels: possible correlation with progressive skin sclerosis, digital ulcers and pulmonary vascular involvement in patients with systemic sclerosis. Acta Derm Venereol
25.
Zurück zum Zitat Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M (2011) Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc Med 21(7):204–10CrossRefPubMed Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M (2011) Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant. Trends Cardiovasc Med 21(7):204–10CrossRefPubMed
Metadaten
Titel
Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis
verfasst von
Ivone Silva
Cristiana Almeida
Andreia Teixeira
José Oliveira
Carlos Vasconcelos
Publikationsdatum
26.02.2016
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 7/2016
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-016-3219-8

Weitere Artikel der Ausgabe 7/2016

Clinical Rheumatology 7/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.